The history of Sildenafil presents a complex picture for shareholders. While the initial launch generated significant returns, the lapse of its patent opened the floodgates to generic versions, dramatically diminishing market share. This poses a specific risk for firms relying on similar blockbuster products, suggesting that a unquestioning partici

The history of Viagra, and its developer copyright, presents a challenging case study for investors. Initially a blockbuster drug, generating billions in sales , its patent expiration created a wave of lower-priced alternatives , significantly eroding its position . While some pharmaceutical companies may attempt to capitalize on similar conditions